The Food and Drug Administration (FDA) has granted clearance for a new feature in Brainomix’s 360 Stroke solution, allowing physicians to evaluate ischemic core volume from universally available non-contrast computed tomography (NCCT) images.

US stroke centres have studied and validated this patented feature, showing equivalency to core volume assessments derived from CT perfusion and magnetic resonance imaging (MRI).

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The new feature addresses a critical gap in stroke triage by providing medical professionals throughout stroke networks with “expert-level” insights.

These insights aim to enhance the decision-making process regarding patient treatment and transfer, relying on routine brain scans.

Brainomix 360 claims to be the sole stroke AI imaging tool that displayed an influence on stroke treatment rates.

Brainomix CEO and co-founder Dr Michalis Papadakis said: “This key expansion of our Brainomix 360 platform marks a critical advancement in stroke imaging and reinforces our mission to transform stroke care through cutting-edge technology.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Brainomix 360 empowers stroke teams by unlocking real-time, high-precision insights that can help expand patient access to life-changing treatments, including both thrombolysis and mechanical thrombectomy, for use up to 24 hours after stroke onset.”

A substantial study encompassing data from more than 450,000 subjects across three years highlighted that the use of Brainomix 360 was linked to an increase of over 50% in mechanical thrombectomy rates.

Last month, the company completed a Series C funding round, raising £14m ($18m) to support the deployment of the Brainomix 360 Stroke solution across the US to further its commercial expansion.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact